Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

Author： Arslan Cagatay Sari Ebru Aksoy Sercan Altundag Kadri

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.1, 2011-01, pp. : 21-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S. Perry Caroline M.

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

Lapatinib: In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

By Curran Monique P.

Drugs, Vol. 70, Iss. 11, 2010-07 ,pp. : 1411-1422

Adis International

Access to resources Recommend Favorite

Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer

By Montemurro Filippo Rossi Valentina Geuna Elena Valabrega Giorgio Martinello Rossella Milani Andrea Aglietta Massimo

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 15, 2012-10 ,pp. : 2143-2156

Informa Healthcare

Access to resources Recommend Favorite

Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. : 263-274

Bentham Science Publishers

Access to resources Recommend Favorite

Fulvestrant: A Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women

By Croxtall Jamie D. McKeage Kate

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 363-380

Adis International

Access to resources Recommend Favorite